CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announces that ZEVALIN®is now available at hospitals in Hong Kong to patients with indicated non-Hodgkin’s lymphoma (NHL), including at Hong Kong Sanatorium & Hospital. The drug will be supplied by CASI and its local partner, Global Medical Solutions Hong Kong Limited.
ZEVALIN (ibritumomab tiuxetan) is a FDA-approved product indicated for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin’s lymphoma (NHL). It is also indicated for the treatment of patients with previously untreated follicular non-Hodgkin’s Lymphoma who achieve a partial or complete response to first-line chemotherapy. ZEVALIN builds on the combined therapeutic effects of a targeted biologic monoclonal antibody augmented with a beta-emitting radioisotope. CASI Pharmaceuticals holds the exclusive marketing rights to ZEVALIN in greater China (including Taiwan, Hong Kong and Macau) and is launching the drug in Hong Kong as the first of its marketing territories.
http://www.prnewswire.com/news-releases/casi-pharmaceuticals-announces-availabilty-of-anti-cancer-drug-zevalin-in-hong-kong-for-non-hodgkins-lymphoma-300115238.html
Recent Comments